Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105

The FDA approval of bevacizumab (Avastin(®), Genentech/Roche), a monoclonal antibody raised against human VEGF-A, as second-line therapy for colon and lung carcinoma validated the approach of targeting human tumors with angiogenesis inhibitors. While the VEGF/VEGFR pathway is a viable target for ant...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Immunol Immunother
Asıl Yazarlar: Wood, Laurence M., Pan, Zhen-Kun, Guirnalda, Patrick, Tsai, Peter, Seavey, Matthew, Paterson, Yvonne
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer-Verlag 2011
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4438988/
https://ncbi.nlm.nih.gov/pubmed/21431419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-011-1002-x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller